IL257138A - Chimeric antigen receptors with integrated controlled activities - Google Patents

Chimeric antigen receptors with integrated controlled activities

Info

Publication number
IL257138A
IL257138A IL257138A IL25713818A IL257138A IL 257138 A IL257138 A IL 257138A IL 257138 A IL257138 A IL 257138A IL 25713818 A IL25713818 A IL 25713818A IL 257138 A IL257138 A IL 257138A
Authority
IL
Israel
Prior art keywords
chimeric antigen
antigen receptors
controllable functions
integrated controllable
integrated
Prior art date
Application number
IL257138A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Publication of IL257138A publication Critical patent/IL257138A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL257138A 2015-08-24 2018-01-24 Chimeric antigen receptors with integrated controlled activities IL257138A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570545 2015-08-24
EP15202592 2015-12-23
PCT/EP2016/069918 WO2017032777A1 (en) 2015-08-24 2016-08-24 Chimeric antigen receptors with integrated controllable functions

Publications (1)

Publication Number Publication Date
IL257138A true IL257138A (en) 2018-03-29

Family

ID=56842804

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257138A IL257138A (en) 2015-08-24 2018-01-24 Chimeric antigen receptors with integrated controlled activities

Country Status (12)

Country Link
US (1) US10988542B2 (cg-RX-API-DMAC7.html)
EP (1) EP3341410B1 (cg-RX-API-DMAC7.html)
JP (1) JP6894430B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180042361A (cg-RX-API-DMAC7.html)
CN (1) CN107922498A (cg-RX-API-DMAC7.html)
AU (1) AU2016313082B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018002189A2 (cg-RX-API-DMAC7.html)
CA (1) CA2995632C (cg-RX-API-DMAC7.html)
IL (1) IL257138A (cg-RX-API-DMAC7.html)
MX (1) MX2018001533A (cg-RX-API-DMAC7.html)
RU (1) RU2018109426A (cg-RX-API-DMAC7.html)
WO (1) WO2017032777A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
CA2948462A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
EP3184548A1 (en) * 2015-12-23 2017-06-28 Miltenyi Biotec GmbH Chimeric antigen receptor with cytokine receptor activating or blocking domain
SI3443096T1 (sl) * 2016-04-15 2023-07-31 Novartis Ag Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CA3056227A1 (en) * 2017-03-13 2018-09-20 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
KR102624509B1 (ko) 2017-03-27 2024-01-12 싱가포르국립대학교 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
EP3600356A4 (en) 2017-03-27 2020-12-23 National University of Singapore TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
JOP20180027A1 (ar) * 2017-03-28 2019-01-30 Cell Design Labs Inc بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
JP2020512825A (ja) * 2017-04-12 2020-04-30 ファイザー・インク 条件的親和性を有する抗体およびその使用の方法
EP3624811A4 (en) * 2017-05-19 2021-03-10 The Regents of The University of California ANTIBODY-BASED CHEMICAL INDUCED DIMERIZER (ABCID) AS A MOLECULAR SWITCH FOR REGULATING CELL THERAPIES
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
CN107312797B (zh) * 2017-07-28 2021-06-18 广州中科蓝华生物科技有限公司 一种蛋白调控系统及其制备方法和应用
KR20200055037A (ko) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
EP3723787A4 (en) 2017-12-14 2021-09-01 Bluebird Bio, Inc. DARIC INTERLEUKIN RECEPTORS
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス， インク．Ｆｌｏｄｅｓｉｇｎ Ｓｏｎｉｃｓ， Ｉｎｃ． 音響トランスデューサドライバ及びコントローラ
SG11202005307RA (en) * 2017-12-14 2020-07-29 Bluebird Bio Inc Nkg2d daric receptors
EP3502130A1 (en) 2017-12-20 2019-06-26 St. Anna Kinderkrebsforschung Ligand regulated protein-protein interaction system
CN111542535A (zh) 2017-12-20 2020-08-14 圣安娜儿童癌症研究中心 配体调控的蛋白-蛋白相互作用系统
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
WO2019154313A1 (zh) 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
CA3098014A1 (en) * 2018-04-27 2019-10-31 Crispr Therapeutics Ag Anti-bcma car-t-cells for plasma cell depletion
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
KR20210068478A (ko) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 콜라겐-국재화된 면역조정성 분자 및 그의 방법
US20220267435A1 (en) * 2018-10-03 2022-08-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Covalent adaptor synnotch and chimeric antigen receptors (cars) for programmable antigen-targeting
EP3860643A1 (en) * 2018-10-05 2021-08-11 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CA3125299A1 (en) * 2019-01-04 2020-07-09 The University Of Chicago Systems and methods for modulating rna
CN118546959A (zh) 2019-03-05 2024-08-27 恩卡尔塔公司 Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
CA3138969A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Cd33-binding polypeptides and uses thereof
MX2021013417A (es) 2019-05-04 2021-12-10 Inhibrx Inc Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
CN114040926B (zh) 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
WO2020227474A1 (en) * 2019-05-08 2020-11-12 Bluebird Bio, Inc. Cd33 targeted immunotherapies
CA3139512A1 (en) * 2019-05-08 2020-11-12 Inhibrx, Inc. Cd123 targeted immunotherapies
CN114502586B (zh) 2019-05-08 2025-06-24 瑞泽恩制药公司 Cll-1靶向免疫疗法
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
WO2021087183A1 (en) * 2019-10-31 2021-05-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
WO2021116337A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
CA3186887A1 (en) * 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
EP4590336A1 (en) * 2022-09-20 2025-07-30 Dana-Farber Cancer Institute, Inc. Receptor-mediated endocytosis for targeted degradation and delivery of therapeutic agents
CN119638840A (zh) * 2023-09-15 2025-03-18 东莞市朋志生物科技有限公司 一种抗糖类抗原153的抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530636B2 (en) * 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
PL3300745T3 (pl) 2013-02-15 2020-03-31 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor

Also Published As

Publication number Publication date
CA2995632A1 (en) 2017-03-02
RU2018109426A (ru) 2019-09-26
US20180237533A1 (en) 2018-08-23
WO2017032777A1 (en) 2017-03-02
BR112018002189A2 (pt) 2018-09-18
KR20180042361A (ko) 2018-04-25
JP6894430B2 (ja) 2021-06-30
US10988542B2 (en) 2021-04-27
JP2018525006A (ja) 2018-09-06
EP3341410B1 (en) 2021-06-02
EP3341410A1 (en) 2018-07-04
CA2995632C (en) 2023-02-07
AU2016313082A1 (en) 2018-02-15
AU2016313082B2 (en) 2022-03-31
MX2018001533A (es) 2018-03-15
CN107922498A (zh) 2018-04-17
RU2018109426A3 (cg-RX-API-DMAC7.html) 2020-02-28

Similar Documents

Publication Publication Date Title
IL257138A (en) Chimeric antigen receptors with integrated controlled activities
IL263220B2 (en) Chimeric receptors for the CD33 antigen
IL250536A0 (en) Chimeric antigen receptors
IL251030A0 (en) Chimeric antigen receptors
IL254254B (en) chimeric antigen receptor
IL258527A (en) Chimeric Antigen Receptors Against Sorting Group 30
GB201617290D0 (en) Novel chimeric antigen receptors
ZA201704059B (en) Bcma chimeric antigen receptors
AU2015269219B2 (en) Mesothelin-targeted chimeric antigen receptors and uses thereof
EP3256496A4 (en) Chimeric antigen receptors
IL250202B (en) bcma chimeric antigen receptors
GB201503742D0 (en) Chimeric antigen receptor
SG11201606790XA (en) Chimeric antigen receptor
EP3259352A4 (en) Chimeric antigen receptors and uses thereof
GB201607968D0 (en) Chimeric antigen receptor
GB201610512D0 (en) Chimeric antigen receptor
IL247371B (en) Antibodies from individuals with increased stability
IL266950A (en) Chimeric chlorotoxin receptors
GB201711470D0 (en) Chimeric receptors
GB201519900D0 (en) Chimeric antigen receptor
GB201612844D0 (en) Chimeric antigen receptor
GB201612533D0 (en) Chimeric antigen receptor
GB201604387D0 (en) Chimeric antigen receptor
HK1240770A1 (zh) 嵌合抗原受体
GB201409761D0 (en) Chimeric antigen receptor